36results about How to "Prolong the time of action in the body" patented technology

The invention discloses the tumor gene therapy field, which particularly relates to a RNA interference plasmid-liposome resistant tumor complex of targeting FAK and EGFR. A FAK and EGFR double-gene RNA interference vector prepared by the invention can effectively inhibit the growth of the lung cancer cell of human and can induce the apoptosis; the tumor inhibiting experiment in the vivo also indicates that the FAK and EGFR double-gene RNA interference vector-liposome resistant tumor complex can obviously inhibit the growth of a plurality of the tumor, and the lifetime of the tumor bearing mice is prolonged. In the invention, the FAK and EGFR double-gene RNA interference vector is wrapped through the cationic liposome, and the chemotherapy and the radiotherapy are taken as the resistant tumor medicine of the active component together, compared with each individual operation, the resistant tumor effect is obviously optimized, and both used amounts can be reduced. By adopting the invention, the effect is obvious, the dose can be greatly reduced, the life quality of the patient is improved, and thereby the invention has a good market developing prospect.

The invention provides a thymalfasin sustained release micro-sphere preparation and a preparing method thereof. The thymalfasin sustained release micro-sphere preparation comprises, by micro-sphere weight, 0.1%-30% of thymalfasin, 50%-99.9% of a biodegradable high polymer material which ranges from 5000 Dalton to 200000 Dalton in molecular weight and has the biocompatibility and 0%-20% of other acceptable auxiliary materials on pharmacy. The invention further provides the preparing method for preparing the thymalfasin sustained release micro-sphere preparation, namely a high-pressure static microcapsule molding method. By means of thymalfasin sustained release micro-spheres prepared with the method, effective embedding and sustained release of the thymalfasin are achieved, the sustained release effect can reach 40 days, the toxic and side effect of the thymalfasin can be effectively reduced, the bioavailability is improved, and the metabolic half-life is prolonged; and meanwhile, the number of drug administration times is decreased, and economic and mental burdens of a patient are relieved.

The invention related to 3-alkoxy-substituent-2-pyrazinyl formamide compounds with a structure represented by the general formula I, and an application thereof in preparing antiviral medicines. The compounds provided by the invention perform antiviral effects in vivo through a process of being metabolized into T1105 or T705 by esterase or P450 enzyme. Compared with prototype medicines T1105 or T705, the compounds with the general formula I have substantial advantages of high bioavailability and long in-vivo action time.

The invention innovatively provides sphaelactone dimethylamine lipidosome.The lipidosome uses a similar surface active substance as the carrier and includes medicine effective components, namely, sphaelactone dimethylamine and derivatives of sphaelactone dimethylamine.The application of the sphaelactone dimethylamine lipidosome in medicine for treating the pulmonary fibrosis is achieved.Compared with the prior art, the sphaelactone dimethylamine lipidosome atomizing inhalant with the PSMC as the carrier and the application of the inhalant in medicine for treating the pulmonary fibrosis have the advantages that through the phospholipid bilayer structure, the same as that of cytomembrane, of PSMC and the lubricating and protecting effects of phospholipids, the combining rate of medicine and alveolar cells is increased, the pharmacokinetics characteristics are changed, the medicine in-vivo acting time is prolonged, and the treatment effect of sphaelactone dimethylamine on the pulmonary fibrosis is remarkably improved.

The invention provides a thymalfasin slow release microsphere preparation and a preparation method thereof. The thymalfasin slow release microsphere preparation is a preparation prepared from thymalfasin accounting for 0.1-30% of the weight of microspheres, a biodegradable and biocompatible polymer material accounting for 50-99.9% of the weight of the microspheres and having a molecular weight of 5000-200000dalton, and other pharmaceutically acceptable auxiliary materials accounting for 0-20% of the weight of the microspheres. The invention also provides the preparation method of the thymalfasin slow release microsphere preparation. The method is a high-voltage electrostatic microcapsule molding method. The thymalfasin slow release microsphere preparation realizes effective embedding and slow releasing of thymalfasin, can continuously release for 40d, and also has the advantages of effectively reduction of the toxic and side effects of thymalfasin, improvement of the bioavailability, prolongation of the metabolism half life, administration frequency reduction, and reduction of the economy and spirit burden of patients.

Bacilliis natto NLSSc with the preservation number CGMCC No. 0724 is Gram staining positive, non-acid fast, straight or near straight, (0.6-0.8)x(1.5-2.0) micron sized and aerobic; has mesial and un-swelled spore with the spore number inside one sporange cell not more than one, meso diamino heptane diacid and glycin contained in the cell wall, no characteristic saccharum and peripheral flagellum; and can be grown well in five kinds of natural organic culture medium and can form relatively thick mycoderm and butter fat colored colony with smooth edge in soybean cake powder culture medium. Bacilliis natto can be cultured in culture medium with nitrogen source to obtain thrombus dissolving matter natto kinase and the cultured matter may be extracted to obtain powdered matter as the additive for thrombolytic health food.

The invention discloses an epothilone B polymer nanoparticle preparation for treating tumors and a preparation method thereof. The polymer nanoparticle preparation is composed of epothilone B, a polymer carrier material and a lyoprotectant; the nanoparticle preparation has a particle size of 10-200 nm. The preparation method of the nanoparticle preparation comprises the following steps: mixing an organic solvent solution of the polymer carrier material and epothilone B with an aqueous phase containing an emulsifier according to a ratio, homogenizing, removing an organic solvent, concentrating, filtering and disinfecting, and lyophilizing to obtain the preparation. By changing the prescription process parameters of the polymer carrier material such as composition, concentration and organic solvent removal temperature, drug loading capacity, drug release speed and other features are adjusted; the preparation prepared herein has good slow release effect and can effectively prevent epothilone B from being hydrolyzed and deactivated by esterase in body, significantly prolonging in-vivo circulation time, improving antitumor activity and lowering medicine toxicity.

This invention relates to hindered carbamate derivatives that are muscarinic receptor antagonists and antagonists, pharmaceutical compositions comprising such compounds, and methods of preparing these compounds.

The invention discloses the tumor gene therapy field, which particularly relates to a RNA interference plasmid-liposome resistant tumor complex of targeting FAK and EGFR. A FAK and EGFR double-gene RNA interference vector prepared by the invention can effectively inhibit the growth of the lung cancer cell of human and can induce the apoptosis; the tumor inhibiting experiment in the vivo also indicates that the FAK and EGFR double-gene RNA interference vector-liposome resistant tumor complex can obviously inhibit the growth of a plurality of the tumor, and the lifetime of the tumor bearing miceis prolonged. In the invention, the FAK and EGFR double-gene RNA interference vector is wrapped through the cationic liposome, and the chemotherapy and the radiotherapy are taken as the resistant tumor medicine of the active component together, compared with each individual operation, the resistant tumor effect is obviously optimized, and both used amounts can be reduced. By adopting the invention, the effect is obvious, the dose can be greatly reduced, the life quality of the patient is improved, and thereby the invention has a good market developing prospect.

The present invention provides a hyaluronate-containing composition comprising a two-gel system composed of a cross-linked hyaluronate gel and a non-cross-linked hyaluronate gel, the pH of the two-gel system 6.0-8.0, the average particle size is 100-300μm, and the kinematic viscosity is 10-80mm 2 / s, the pushing force is 5‑30N. The present invention also provides a method for preparing a hyaluronate-containing composition, comprising: using the first hyaluronic acid or hyaluronate to prepare a cross-linked hyaluronate gel; using the second hyaluronic acid or hyaluronate Hyaluronate to prepare non-cross-linked hyaluronate gel; mixing the cross-linked hyaluronate gel and the non-cross-linked hyaluronate gel, followed by high temperature treatment to obtain a double gel system. Compared with traditional hyaluronic acid water-light products, the composition prepared by the present invention has enhanced anti-hyaluronidase ability, longer in vivo action time, low gel viscosity, high slip, enhanced fluidity, and easier clinical use. Pushing operation can reduce side effects such as skin bumps and redness.

The invention discloses an exenatide modified compound, a use of the exenatide modified compound in preparation of a medicine which serves as a GLP-1 receptor stimulant, a use of the exenatide modified compound in preparation of medicines used for preventing and / or curing diseases and / or symptoms relevant to low GLP-1 receptor activity, a use of the exenatide modified compound in preparation of medicines used for diseases and / or symptoms relevant to carbohydrate metabolism, a use of the exenatide modified compound in preparation of medicines used for diabetes, a use of the exenatide modified compound in preparation of medicines used for fatty liver, and a use of the exenatide modified compound in preparation of medicines used for weight losing.

The invention discloses a method for preparing a Gd3<+> magnetic resonance imaging contrast agent with graphene oxide serving as a carrier, and belongs to the technical field of preparation of medical materials. The method comprises the following steps of: 1) dispersing graphene oxide into distilled water to obtain a graphene oxide dispersing solution; 2) adding an alkaline substance and chloroacetic acid or sodium monochloroacetate to the graphene oxide dispersing solution, ultrasonically dispersing, centrifugally washing and processing, and dialyzing to obtain carboxylation graphene oxide; and 3) dispersing the carboxylation graphene oxide into the distilled water to obtain a carboxylation graphene oxide dispersing solution, adding an aqueous solution of gadolinium salt to the carboxylation graphene oxide dispersing solution, adding a DTPA (Diethylene Triamine Pentacetic Acid) aqueous solution after the stirring reaction is done, uniformly mixing to obtain a mixing solution, and dialyzing to obtain carboxylation graphene oxide with Gd3<+> loaded on the surface, thus obtaining the Gd3<+> magnetic resonance imaging contrast agent. The method is simple and feasible, and the Gd3<+> is firmly loaded; and the preparation magnetic resonance imaging contrast agent is high in water-borne dispersion stability and has high longitudinal relaxation rate.

The invention discloses a suspension preparation of temperature change painless nano sulfadiazine metallic compound hyaluronic acid. The formula comprises a sulfadiazine metallic compound, a hyaluronic acid substance, an analgetic, a dispersing agent aid, a suspension aid and water, wherein the sulfadiazine metallic compound comprises sulfadiazine silver and sulfadiazine zinc; the hyaluronic acid substance is sourced from biological fermentation and animal tissue extraction and the like and can be hyaluronic acid or hyaluronate or crosslinked hyaluronic acid or crosslinked hyaluronate; the analgetic comprises ropivacaine, bupivacaine, levobupivacaine, lidocaine and other local anesthetics or combination of the local anesthetics; the dispersing agent aid comprises chlorhexidine, Tween series, oleic acid or sodium oleate; the suspension aid can comprise glycerinum, celluloses, poloxamer series and hyaluronic acid substances. The suspension preparation is mainly used for burn, scald or the surface of a wound caused by explosion or anabrosis, has the main clinical characteristics that pain is rapidly relieved, the surface of the wound is subjected to rapid film formation and rapid healing of the wound is promoted, and the conventional main administration modes refer to spraying, smearing and coating.

Disclosed are a 3-alkoxy-substituted-2-pyrazinyl formamide compound having a structure represented by formula I and use thereof in preparing anti-viral medications. The compound disclosed exerts anti-viral effects in vivo by means of metabolism into T1105 or T705 through esterate or P450 enzyme.

The invention relates to the technical field of medicine and cosmetics, in particular to lipidosome preparation formulation of 4-(1- phenethyl)-1 and 3-dihydroxy benzene and a preparation method thereof. The invention prepares the 4-(1- phenethyl)-1, 3-dihydroxy benzene into lipidosome, overcomes the defects of the insufficient application of existing 4-(1- phenethyl)-1 and 3-dihydroxy benzene inpercutaneous administration preparation and cosmetics, improves the stability and percutaneous performance of the 4-(1- phenethyl)-1and 3-dihydroxy benzene and reduces the acrimony of the 4-(1- phenethyl)-1 and 3-dihydroxy benzene for the skin, thus better exerting the healing effect.

The invention discloses an insulin modification method. Chemical coupling is adopted to combine a water-soluble polymer and the insulin through covalent bonding, wherein firstly the insulin is dissolved in a solvent, triethylamine and di-tert-butyl dicarbonate are added and stirred for a reaction, and a product A is obtained through freeze-drying and separation; then, a water-soluble polymer monomer is dissolved in a solvent, an RAFT reagent and an initiator are added for a reaction to obtain a product B; the product A and the product B are weighed, a solvent triethylamine is added, a productC is obtained through dialysis and freeze-drying, the product C is dissolved in water, trifluoroacetic acid is added for a reaction, and a coupled product D of the polymer and the insulin is obtainedthrough dialysis and freeze-drying. The chemically modified insulin is protected from degradation and inactivation by enzymes and the acid environment in the gastrointestinal environment through the water-soluble polymer, so that the degradation of the digestive enzymes of the gastrointestinal tract is effectively inhibited, and the product property is stable.